Solid Tumor Diagnostics Platform Innovator. Developed and patented the SnapPath(R) Cancer Diagnostics System and PathMap (R) Functional Signaling Profiles. SnapPath is the only system able to generate purified populations of live solid tumor cancer cells from fresh, unfixed samples (xenografts, tumorgrafts or clinical samples) in a rapid and standardized manner. Automated, fluidics-based, highly customizable. Technician-friendly, script-controlled robotics. Preserves molecular integrity of live cells for ex vivo exposure to targeted drugs, other chemotherapies, immunotherapies and combinations on SnapPath. Compatible with any solid tumor for which fresh tissue samples are available. Provides DIRECT information on response of cell signaling pathways. Enables PathMAP(R) Functional Signaling Profiles, a new class of highly predictive biomarker tests derived from exposure of live solid tumor cells to targeted drugs, other chemotherapies, immunotherapies and combinations on SnapPath.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
SnapPath(R) Cancer Diagnostics System
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Geography-specific distribution rights for distribution of SnapPath available.